Software Matches Genomic Test Results to Cancer Treatment Options, Including Trials and Experimental Drugs, via Intelligent Search and Molecular Science
SAN FRANCISCO, CA--(Marketwired - Mar 7, 2016) - MolecularMatch, a personalized cancer treatment company that works with labs, hospitals, genomic cores and physicians to connect cancer patients to treatment options, launched its MM LAB software today at The Molecular Medicine Tri-Conference.
MM LAB, which is available through an online portal, allows pathology labs and others to match patients' test results to personalized cancer treatments, including clinical trials and experimental drugs, in real-time.
It is based on the already available, public-facing MolecularMatch cancer treatment search engine.
"We've taken a time-consuming, manual task that usually happens after lab results are returned, and automated it with an intelligent, science-based, Google-like search," said MolecularMatch CEO Kevin Coker. "With MM LAB, oncologists and patients get test results and easily understandable treatment options all at once, rather than having to wait even longer to find and begin a course of treatment."
After test results are matched to treatments in MM LAB, the options are curated by the client laboratory's staff and included in the reports sent back to physicians and patients.
- Molecular science / artificial intelligence based algorithms -- pioneered in the public-facing search engine -- match patients' exact, genetic cancer type to the treatment options best suited to combat their variant of the disease
clinical trials, drug and medical databases, websites, individual drug
labels and scientific and oncological journals
- Includes 300,000 biomedical documents checked against more than 700,000 biomedical facts - resulting in nearly 2.5 billion indexed combinations
- Additional data and curation are fed into MM LAB to enhance its effectiveness in the lab environment
- Maintained and updated by MolecularMatch scientists, physicians and engineers
"MolecularMatch provides a powerful resource for molecular pathologists," said Christopher Corless, MD, PhD., Chief Medical Officer of OHSU Knight Diagnostic Laboratories. "Identifying treatment options -- particularly trials -- is a time-consuming task. The MolecularMatch platform allows our team to efficiently match complex genomic test data to appropriate treatment options in much less time."
MolecularMatch at Molecular Med Tri-Con:Founder & Chief Medical Officer James W. Welsh will speak at the Models for Cancer Immunotherapy Session on Tuesday, March 8 at 11:15 a.m. PST
CEO Kevin Coker will discuss MM LAB and Molecular Match at the Plenary Session on Wednesday, March 9 at 8:00 a.m. PST
MolecularMatch will demo MM LAB at booth 708, North Hall D, Moscone North Convention Center (map) at the following times:
- Monday 3/7 - 6:00 to 7:30 p.m. PST
- Tuesday 3/8 - 9:00 a.m. to 5:00 p.m. PST
- Wednesday, 3/9 - 10:00 a.m. to 1:50 p.m. PST
For more information on MolecularMatch, and to access its public-facing cancer treatment search engine, please visit http://molecularmatch.com.
About MolecularMatchFounded in 2014, MolecularMatch is a personalized cancer treatment platform that works with labs, hospitals, genomic cores and physicians to connect patients with the treatment options best-suited to their genetic profiles. It's searchable, high speed database provides real-time results that arm doctors, patients and researchers with specialized information, smarter resources and better connections in the fight against cancer.
ContactCodeword for MolecularMatch